Article

NTG treatment plan similar to POAG management

San Francisco - Results from the Collaborative Normal Tension Glaucoma Study provided the first and still best evidence that lowering IOP by 30% in patients with normal-tension glaucoma (NTG) does prevent or slow the progression of glaucomatous visual field loss, said Donald L. Budenz, MD, MPH, associate professor, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

San Francisco - Results from the Collaborative Normal Tension Glaucoma Study provided the first and still best evidence that lowering IOP by 30% in patients with normal-tension glaucoma (NTG) does prevent or slow the progression of glaucomatous visual field loss, said Donald L. Budenz, MD, MPH, associate professor, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

In developing a treatment plan for the patient with NTG, Dr. Budenz said that he first assesses IOP at different times of the day in order to establish the baseline level that will be used to set a target. Treatment is usually initiated with a prostaglandin analogue and aims to lower IOP by at least 30%, although a more aggressive goal may be pursued if the patient has already sustained significant glaucomatous damage.

“A prostaglandin is my drug of first choice in this condition because it has the potential to reach the target IOP with single-agent therapy and so it provides cost and compliance benefits for the patient. Theoretically, a prostaglandin can also lower IOP below episcleral venous pressure, which may be needed in patients with NTG,” he said.

If prostaglandin monotherapy is ineffective, he adds a second medication, choosing from among a topical carbonic anhydrase inhibitor, beta-blocker or alpha-agonist, turns to selective laser trabeculoplasty as needed to reach the IOP goal, and proceeds to trabeculectomy with an antifibrotic agent as a last resort.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.